Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

78%

7 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4

5(62.5%)

Phase 3

2(25.0%)

Phase 2

1(12.5%)

8Total

Phase 4(5)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06377072Phase 3Completed

Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy

Role: lead

NCT07241520Phase 3Recruiting

Phase III Clinical Trial of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke

Role: lead

NCT06202378Phase 2Completed

Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke

Role: lead

NCT07153744Phase 4Not Yet Recruiting

Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction

Role: lead

NCT06755671Recruiting

A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms

Role: lead

NCT04897126Phase 4Completed

Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery

Role: lead

NCT04984954Phase 4Unknown

Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction

Role: lead

NCT03072121Phase 4Unknown

Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization

Role: collaborator

NCT01897805Phase 4Unknown

A Trial to Evaluate Efficacy of Heart-protecting Musk Pill

Role: lead

All 9 trials loaded